Greca Z.
- Country
- Italy
- Department
- S.C. Cardiologia
Research Overview
- Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction
- Evaluation of P2Y12 Inhibitor De-Escalation Regimens on Platelet Reactivity in High Bleeding Risk Patients with Acute Coronary Syndrome Post-Stenting
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of Intravenous Sodium Iodide (FDY-5301) in Anterior ST-Elevation Myocardial Infarction Patients
Data & Insights
Has run more than one trial at 46 of 397 partner sites.
Specializations
Acute Coronary Syndromes and Myocardial Infarction
Greca Zanda is involved in clinical research focused on acute coronary syndrome, anterior ST-elevation myocardial infarction, and broader myocardial infarction care, with interest in early post-event cardiovascular risk reduction and secondary prevention.
- STEMI and NSTEMI
- Post-infarction cardiovascular event prevention
- Inflammation-targeted cardioprotection
Her work also extends to strategies addressing residual risk after infarction, including therapies aimed at reducing recurrent major adverse cardiovascular events.
Atherosclerotic Cardiovascular Disease and Lipid-Lowering Therapy
Her research profile includes atherosclerotic cardiovascular disease, elevated lipoprotein(a), and intensive lipid management in patients at high cardiovascular risk.
- PCSK9 inhibition
- Lipoprotein(a)-related risk
- Prevention of coronary events
She is also engaged in studies evaluating therapies designed to lower long-term risk of coronary heart disease, myocardial infarction, and urgent coronary revascularization.
Atrial Fibrillation and Left Atrial Appendage Closure
Another major area of interest is atrial fibrillation, particularly in patients unsuitable for oral anticoagulation and in those undergoing percutaneous left atrial appendage closure with the Amulet device.
- Stroke prevention
- Thromboembolic risk reduction
- Antiplatelet treatment strategies
Her activity includes research on optimizing antithrombotic approaches after device-based closure and on reducing bleeding and ischemic complications in this population.
Heart Failure, Metabolic Disease, and Cardiometabolic Risk
Greca Zanda is involved in studies of heart failure with preserved or mildly reduced ejection fraction, obesity, type 2 diabetes, and hypertension in patients with established cardiovascular disease.
- Heart failure event prevention
- Cardiometabolic intervention
- Cardiovascular mortality reduction
Her therapeutic focus also includes approaches targeting inflammatory and metabolic pathways in patients with high-risk cardiovascular profiles.
Oncology and Perioperative Treatment Strategies
Her clinical research landscape also covers selected oncologic conditions, including locally advanced rectal cancer and metastatic HER2-positive breast cancer, with attention to treatment combinations used in the neoadjuvant and systemic setting.
- Rectal cancer
- HER2-positive breast cancer
- Neoadjuvant treatment optimization
These activities reflect involvement in therapeutic areas where cardiovascular and oncologic care intersect with disease control and treatment selection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.